$CTSOJun 18, 2026, 12:46 PMAI processed
CytoSorbents (CTSO) to present at Life Sciences Forum June 24; investor 1-on-1s June 30
AI Summary
CytoSorbents (CTSO) said CEO Phillip Chan will present at the VirtualInvestorConferences Life Sciences Forum on June 24 with a Zacks-hosted Q&A including CFO Peter Mariani, and management will hold one-on-one investor meetings on June 30 to provide an update. The appearances are an investor-access catalyst where management is likely to discuss corporate and regulatory progress (the company holds two FDA Breakthrough Device designations for DrugSorb-ATR) and its target to reach cash-flow break-even in H2 2026; no new clinical data, approvals, or financial results were disclosed.
Positives
- CEO presentation and Zacks-hosted Q&A scheduled June 24 increases company visibility to investors
- Management scheduled one-on-one investor meetings on June 30 for deeper investor access
- Company holds two FDA Breakthrough Device designations for DrugSorb-ATR (regulatory progress)
Negatives
- No new clinical data, regulatory approvals, or financial results announced in these events
- CytoSorb (CytoSorb®) is not yet approved or cleared in the U.S.
- Cash-flow break-even in H2 2026 is a target and not guaranteed